Clik here to view.
Bigfoot Biomedical taps Abbott to collaborate on automated insulin delivery tech
Abbott (NYSE:ABT) and Bigfoot Biomedical said today that the companies inked a deal to develop and commercialize diabetes management systems. The collaboration will bring together Abbott’s FreeStyle...
View ArticleClik here to view.
Bigfoot Biomedical’s CEO talks disruption in diabetes management tech
Bigfoot Biomedical is a highly competitive player in medtech’s race to develop an artificial pancreas. The 50-person company has made rapid progress towards developing a smart, automated insulin...
View ArticleClik here to view.
Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment
Just one week after Abbott (NYSE:ABT) said it inked a deal with Bigfoot Biomedical to develop an automated diabetes management system, CEO Miles White told analysts that he thinks Bigfoot is playing...
View ArticleClik here to view.
Biotech, pharma chime in over Trump’s move to halt immigration program
On Tuesday, biotech and pharmaceutical companies urged president Donald Trump to reconsider his decision to end former president Barack Obama’s policy protecting undocumented immigrants who arrived in...
View ArticleClik here to view.
Convenience, compliance & control: How Insulet is changing insulin delivery tech
Shacey Petrovic spent nearly a decade trying to convince her diabetic father to switch to an insulin pump, rather than inject himself multiple times each day. But he was wary of the tubing and other...
View ArticleClik here to view.
Why Bigfoot Biomedical’s CEO thinks the diabetes industry has a data problem
Bigfoot Biomedical‘s chief executive is excited about Abbott‘s (NYSE:ABT) latest regulatory win – and it’s not just because the two companies have an established partnership. Yesterday, the FDA...
View ArticleClik here to view.
Here’s how the diabetes industry’s leaders think about patient-centered R&D
Designing devices centered around patients is a goal espoused by nearly all device companies nowadays, as they aim to make products that people want to use and can incorporate into their everyday...
View ArticleClik here to view.
Ypsomed to supply Bigfoot with insulin infusion sets for pivotal trial
Ypsomed plans to supply Bigfoot Biomedical with a modified version of its Orbit infusion set for the pivotal trial of Bigfoot’s automated insulin delivery system, the companies said today. Ypsomed’s...
View ArticleClik here to view.
Bigfoot compares trial data with modeling results for automated insulin...
Bigfoot Biomedical touted data last week at this year’s Diabetes Technology Meeting showing that results from a feasibility study evaluating the company’s automated insulin delivery system closely...
View ArticleClik here to view.
Bigfoot Biomedical CEO hits back against CMS over data-sharing decision
Bigfoot Biomedical CEO Jeffrey Brewer has spoken out about a recent data-sharing decision made by CMS, saying that he plans to lobby Medicare to reverse its latest move. Earlier this year, CMS said it...
View ArticleClik here to view.
Bigfoot Biomedical raises $37m in Series B
Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor,...
View ArticleClik here to view.
SFC Fluidics inks deal with JDRF to develop automated insulin delivery system
SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable...
View ArticleClik here to view.
Bigfoot brings Series B total to $55m with new investment from Abbott
Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas,...
View ArticleClik here to view.
How Bigfoot Biomedical’s CEO wants to boost diabetes management
Jeffrey Brewer faced the biggest challenge of his life when his 7-year-old son Sean received a diabetes diagnosis in 2002: Diabetes became the new focus for Brewer’s energy. In his role as CEO at JDRF...
View ArticleClik here to view.
Bigfoot Biomedical inks insulin deal with Eli Lilly
Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The...
View ArticleClik here to view.
Bigfoot Biomedical, Owen Mumford ink deal for pen needles
Bigfoot Biomedical said today that it inked a commercial supply deal to include Owen Mumford‘s Pentips line of pen needles with Bigfoot’s injection system subscription bundles. Milpitas, Calif.-based...
View ArticleClik here to view.
Bigfoot Biomedical inks deal with Pittsburgh health system
Bigfoot Biomedical today announced an agreement with Pittsburgh-based Allegheny Health Network (AHN) to further develop Bigfoot’s Unity investigational insulin delivery wireless platform. The diabetes...
View ArticleClik here to view.
Abbott boosts support for Bigfoot Biomedical and its diabetes treatment tech
Bigfoot Biomedical officials would like to launch the Bigfoot Unity diabetes management program by the end of the year. [Conceptual rendering courtesy of Bigfoot Biomedical]Diabetes treatment tech...
View ArticleClik here to view.
Bigfoot Biomedical raises $55m in Series C
Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round. Abbott (NYSE:ABT) led the funding round with participation from new...
View ArticleClik here to view.
Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer
Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today. Malone, an...
View Article
